Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
NCT ID: NCT00078221
Last Updated: 2008-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
180 participants
INTERVENTIONAL
1999-08-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rheopheresis blood filtration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Dry AMD
* BCVA between 20/32 and 20/125 in at least one eye
* Numerous large plaques (soft drusen)
* No history of HIV, Hepatitis B or C
* Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA
50 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OccuLogix
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irving Siegel, MD
Role: STUDY_DIRECTOR
OccuLogix
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Vitreous Associates
Beverly Hills, California, United States
Aran Eye Associates
Coral Gables, Florida, United States
Retina Health Care
Fort Myers, Florida, United States
UIC Eye Center
Chicago, Illinois, United States
Macula Care
New York, New York, United States
Carolina Eye Associates
Southern Pines, North Carolina, United States
Associated Retinal Consultants
Bala-Cynwyd, Pennsylvania, United States
W. Bradley Kates, MD
Oakville, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pulido JS; Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc. 2002;100:85-106; discussion 106-7.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMD-02-99
Identifier Type: -
Identifier Source: org_study_id